Тромбоз, гемостаз и реология

Tromboz, Gemostaz I Reologiya
scientific and practical journal

ISSN 2078–1008 (Print); ISSN 2687-1483 (online)
2021, Review
2021

Hemorrhagic complications of а novel coronavirus infection: actual clinical problem: 616.15-005

Review
Published 2021-10-04
Irina Simarova
Demikhov City Clinical Hospital, Moscow Healthcare Department; 4 Shkuleva Str., Moscow 109263, Russia; Sklifosovsky Research Institute for Emergency Medicine, Moscow Healthcare Department
ГБУЗ «Городская клиническая больница имени В.П. Демихова Департамента здравоохранения города Москвы»; Россия, 109263 Москва, ул. Шкулева, 4; ГБУЗ «Научно-исследовательский институт скорой помощи имени Н.В. Склифосовского Департамента здравоохранения города Москвы»; Россия, 129010 Москва, Большая Сухаревская площадь, 3
Sergei Perehodov
Demikhov City Clinical Hospital, Moscow Healthcare Department; 4 Shkuleva Str., Moscow 109263, Russia
ГБУЗ «Городская клиническая больница имени В.П. Демихова Департамента здравоохранения города Москвы»; Россия, 109263 Москва, ул. Шкулева, 4
Andrey Bulanov
Sklifosovsky Research Institute for Emergency Medicine, Moscow Healthcare Department; 3 Bolshaya Sukharevskaya Square, Moscow 129010, Russia; Evdokimov Moscow State University of Medicine and Dentistry, Health Ministry of Russian Federation; 20/1 Delegatskaya Str., Moscow 127473, Russia
ГБУЗ «Научно-исследовательский институт скорой помощи имени Н.В. Склифосовского Департамента здравоохранения города Москвы»; Россия, 129010 Москва, Большая Сухаревская площадь, 3; ФГБОУ ВО «Московский государственный медико-стоматологический университет имени А.И. Евдокимова»; Россия, 127473 Москва, Делегатская ул., 20/1

Keywords

COVID‐19
bleedings
anticoagulant therapy
hypofibrinogenemia
  Full Text

Abstract

Summary. Hypercoagulable character of coagulopathy associated with the novel coronavirus infection COVID-19, and the high risk of associated thrombotic complications is a well-known fact. However, there are also case reports of hemorrhagic events in COVID patients in the literature. The review summarizes the publications describing bleedings in coronavirus infection; their overall frequency is on average 4–8%. Gastrointestinal bleeding are prevalent, intermuscular hematomas and hemorrhages in the skin and mucous membranes are frequent. The predictive role of anticoagulants use in therapeutic doses and hypofibrinogenemia is shown. The absence of clear understanding of the pathophysiological mechanisms is noted.

References:

  1. Taylor F.B., Toh C.H., Hoots W.K. et al. Towards definition, clini‐ cal and ladoratory criteria, and a scoring system for disseminated intravascular coagualtion. Thromb Haemost. 2001;86(5):1327–30.
  2. Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coro‐ navirus pneumonia. J Thromb Haemost. 2020;18(4):844–7. DOI: 10.1111/jth.14768.
  3. Zabolotskikh I.B., Kirov M. Yu., Lebedinskii K.M. et al. Anesthesia and intensive care for patients with COVID‐19. Russian Federa‐ tion of anesthesiologists and reanimatologists guidelines. Vestnik intensivnoj terapii imeni A.I. Saltanova. 2021;(S1):9–143. (In Russ.). DOI: 10.21320/1818–474X‐2021‐S1–9–143.
  1. Shah A., Donovan K., McHugh A. Thrombotic and haemorrhagic complications in critical ill patients with COVID‐19: a multi‐ center observational study. Crit Care. 2020;24(1):561–71. DOI: 10.1186/s13054–020–03260–3.
  2. Musoke N., Lo K.B., Albano J. et al. Anticoagulation and bleed‐ ing risk in patients with COVID‐ Thromb Res. 2020;196:227– 30. DOI: 10.1016/j.thromres.2020.08.035.
  3. Helms J., Tacguard C., Severac F. et al. High risk of thrombo‐ sis in patients with severe SARS‐CoV‐2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089– DOI: 10.1007/s00134–020–06062‐x.
  4. Gudima G.O., Khaitov R.M., Kudlay D.A., Khaitov M.R. Molecu‐ lar immunological aspects of diagnostics, prevention and treat‐ ment of coronavirus infection. Immunologiya. 2021;42(3):198–210. (In Russ.). DOI: https://doi.org/10.33029/0206–4952–2021–42– 3–198–210.
  1. Roitman E. V., Bulanov A. Yu., Pechennikov V. M. Low molec‐ ular weight heparins dosing and anti‐factor Xa activity in patients with novel coronavirus infection COVID‐19. Tromboz, gemostaz i reologiya. 2020;(4):57–67. (In Russ.). DOI: 10/25555/ THR.2020.4.0946.
  1. Conti C.B., Henchi S., Coppeta G.P. et al. Bleeding in COVID‐19 severe pneumonia: The other side of abnormal coagulation pattern? Eur J Internal Med. 2020;77:147–9. DOI: 10/1016/j. ejim.2020.05.002.
  2. Jimenez D., Garcia‐Sanchez A., Rali P. et al. Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: A systematic review and meta‐ Chest. 2021;159(3):1182–96. DOI: 10.1016/j.chest.2020.11.005.
  3. Schulman S., Kearon C. Definition of major bleeding in clini‐ cal investigations of antihemostatic medicinal products in non‐ surgical patients. J Thromb Haemost. 2005;3(4):692–4. DOI: 10.1111/j.1538–7836.2005.01204.x.
  4. Patell R., Bogue T., Bindal P. et al. Incidence of thrombosis and hemorrhage in hospitalized cancer patients with COVID‐ J Thromb Haemost. 2020;18(9):2349–57. DOI: 10/1111/jth.15018.
  5. Gulen M., Satar S. Uncommon presentation of COVID‐19: gastro‐ intestinal bleeding. Clin Res Hepatol Gastroenterol. 2020;44(4): e72‐ DOI: 10.1016/j.clinre.2020.05.001.
  6. Al‐Samkari H., Leaf R.S.K., Dzik W.H. et al. COVID‐19 and coag‐ ulation: bleeding and thrombotic manifestations of SARS‐CoV‐ Blood. 2020;136(4):489–500. DOI: 10.1182/blood.2020006520.
  7. Bulanov A. Yu., Simarova I.B., Bulanova E.L. et al. New coronavirus infection COVID‐19: clinical and prognostic significance of plasma fibrinogen level. Vestnik intensivnoj terapii imeni A.I. Saltanova. 2020;(4):42–7. (In Russ.). DOI: 10.21320/1818–474X‐2020–4–42–47.
  1. Patell R., BogueT., Koshy A. et al. Postdischarge thrombosis and hemorrhage in patients with COVID‐ Blood. 2020;136(11):1342–6. DOI: 10/1182/blood.2020007938.